FORMULATION AND EVALUATION OF PRONIOSOMAL GEL BASED TRANSDERMAL DELIVERY OF ATORVASTATIN CALCIUM BY BOX BEHNKEN DESIGN

  • Soujanya C Department of Pharmaceutics, Vishnu Institute of Pharmaceutical Education and Research, Narsapur, Medak.

Abstract

Objective: The aim of this study was to investigate the combined influence of 3 independent variables in the preparation of Atorvastatin proniosomes by Coacervation phase separation method.

Methods: On the basis of the preliminary trials a 3-factor, 3-level Box–Behnken design was employed to study the effect of Cholesterol, soya lecithin and Span 60 independent variable on dependent variables (particle size and % entrapment efficiency). TEM analysis of optimized formulation has demonstrated the presence of individual Proniosomes in spherical shape.

Results: Atorvastatin optimized proniosomal formulation F2 shown better particle size and % entrapment efficiency and also the drug release was 99.72% within 24h in slow and controlled manner when compared with control. Kinetic analysis of drug release profiles showed that the drug release was followed by zero-order manner with Korsmeyer-Peppas model, which implies super case II release kinetics. The particle size and Zeta potential of the optimized atorvastatin proniosomal gel was found to be 65.72 and -10.5 respectively. Optimized batch of Proniosomes was used for the preparation of Atorvastatin-based proniosomal hydrogel by incorporating hydrated Proniosomes to Carbopol matrix to enhance the stability and viscosity of the system.

Conclusion: The enhanced skin permeation for prolonged period of time, may lead to improved efficacy and better patient compliance. This study suggests that proniosomal gel containing atorvastatin could perform therapeutically better effects than the conventional formulations.

Keywords: Atorvastatin, Proniosomes, Box Behnken Design, Span 60, zeta potential

References

1. Singh S, Trivedi S, Jain S. Design and development of proniosome based transdermal delivery of ondansetron hydrochloride. International Journal of Pharmaceutical and Biological Research 210; 3(5): 191-201.
2. Schreier H, Bouwstra J. Liposomes and niosomes as topical drug carriers: Dermal and transdermal drug delivery. J Control Release 1994; 30:1–15.
3. Aggarwal D, Kaur IP. Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system. Int J Pharm 2005; 290:155–159.
4. Wen M.M, Farid R.M, Kaseem A.A. Nano-proniosomes enhancing the transdermal delivery of mefenamic acid, J. Liposome Res 2014; 24:280–289.
5. Aggarwal G, Dhawan S. Psychotropic drugs and transdermal delivery: an overview, Int. J. Pharm. Bio Sci (2010); 1: 1–12.
6. Morrow D.I.J, McCarron P.A, Woolfson A.D, Donnelly R.F. Innovative strategies for enhancing topical and transdermal drug delivery, Open Drug Deliv. J (2007); 1: 36–59.
7. Vyas S.P, Khar R.K. Targeted and Controlled Drug Delivery-Novel Carrier Systems, first ed., CBS Publishers and Distributors. India 2004; 249–279
8. Kaushik D, Mishra P.R, Talegaonkar S. Provesicles as surrogate carrier for improved drug delivery, in: N.K. Jain (Ed.), Progress in Controlled and Novel Drug Delivery System, CBS Publishers and Distributors, India 2004; 59–274.
9. Alia Badawi, Mohamed A, Elnabarawi, Randa Tag A. Elrehem, Bassem A. Fayed. Formulation and Evaluation of Dispersed Permethrin Proniosomes In Powder and Microemulsion-Based Hydrogel Bases for The Treatment of Scabies Int J Pharm Sci, 2016;8(1):221-229.
10. Ankit Aacharya, Kiran Kumar G. B. Mohammed Gulzar Ahmed, Saroj Paudel. A Novel approach to increase the bioavailability of candesartan cilexetil by proniosomal gel formulation: In-Vitro and In-Vivo evaluation. Int J Pharm Sci, 2016;8(1):241-246.
11. Klaus, Florey. Analytical Profiles of Drug Substances, Academic Press, Inc., New York, 2004, 577.
12. Bullen WW, Miller RA, Hayes RN. Development and validation of a high- performance liquid chromatography tandem mass spectrometry assay for Atorvastatin, ortho-hydroxy atorvastatin, and para-hydroxy atorvastatin in human, dog, and rat plasma. Journal of American Society for Mass Spectrometry 1999; 10: 55-66.
13. S. Pankaj T, Rini P.M, Dandagi. Formulation and evaluation of proniosome based drug delivery system of antifungal drug clotrimazole IJPSN 2103; 8(1):1945-5.
14. Vora B, Khopade A.J, Jain N.K. Proniosomes based transdermal delivery of levonorgestrel for effective contraception. J. Control. Release 1998; 54:149–165.
15. Thakur R, Anwer M.K, Shams M.., Ali A, Khar R.K, Shakeel F, Taha E.I. Proniosomal transdermal therapeutic system of losartan potassium: development and pharmacokinetic evaluation. J Drug Target 2009; 17: 442–449.
16. Yousuf M, AhmadM, Usman M, Ketotifen I. Fumarate and Salbutamol Sulphate Combined Transdermal Patch Formulations: In vitro release and Ex vivo Permeation Studies Ali Indian J Pharm Sci 2013; 75(5): 569–577.
17. Rahman S.A, Abdelmalak N.S, Badawi A, Elbayoumy T, Sabry N, Ramly A.E. Formulation of tretinoin-loaded topical proniosomes for treatment of acne: in-vitro characterization, skin irritation test and comparative clinical study, Drug Deliv 2105; 22:731–739.
18. Jaafari MR, Bavarsad N, Bazzaz BSF. Effect of topical liposomes containing Paromomycin Sulfate in the course of Leishmania major infection in susceptible BALB/Mice anti-microbial agents and chemotherapy. Am Soc Microbiol 2009; 53:2259–65.
19. Ruan G, Feng SS. Preparation and Characterization of Poly (lactic acid) - poly (ethylene Glycol)-poly lactic acid (PLA-PEG-PLA) microspheres for the controlled release of Paclitaxel. Biomaterials 2003; 24: 5307-44.
20. Rahman SA, Abdelmalak NS, Badawi A, Elbayoumy T, Sabry N, El Ramly A. Formulation of tretinoin-loaded topical proniosomes for treatment of acne: in-vitro characterization, skin irritation test and comparative clinical study. Drug Deliv. 2015; 22(6): 731-9.
21. El-Maghraby G.M, Ahmed A.A, Osman M.A. Penetration enhancers in proniosomes as a new strategy for enhanced transdermal drug delivery. Saudi Pharm. J 2015; 23:67–74.
22. Balch D.A, Cooke R.A. A study of the composition of hen’s egg shell membranes, Ann. Biol. Anim. Biochim. Biophys. 10 (1970) 13–25.
23. Yasam V.R, Jakki S.L, Natarajan J, Kuppusamy G. A review on novel vesicular drug delivery: proniosomes, Drug Deliv 2014; 21: 243–249.
24. Akhtar M, Imam S.S, Ahmad M.A, Najmi A.K, Mujeeb M, Aqil M. Neuroprotective study of Nigella sativa-loaded oral provesicular lipid formulation: in-vitro and ex-vivo study, Drug Deliv 2014; 21: 487–494.
25. Rahman SA, Abdelmalak NS, Badawi A, Elbayoumy T, Sabry N, El Ramly A. Formulation of tretinoin-loaded topical proniosomes for treatment of acne: in-vitro characterization, skin irritation test and comparative clinical study. Drug Deliv 2015; 22(6): 731-9.
26. Ibrahim M.M.A, Sammour O.A, Hammad M.A, Megrab N.A. In-vitro evaluation of proniosomes as a drug carrier for flurbiprofen, AAPS PharmSciTech 2008; 9: 782–790.
27. Draize J.H, Woodard G, Calvery H.D. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes, J. Pharm. Exp. Ther 1944; 82: 377–390.
Statistics
4 Views | 22 Downloads
How to Cite
C, S. “FORMULATION AND EVALUATION OF PRONIOSOMAL GEL BASED TRANSDERMAL DELIVERY OF ATORVASTATIN CALCIUM BY BOX BEHNKEN DESIGN”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 12, no. 2, Jan. 2019, pp. 233-41, https://innovareacademics.in/journals/index.php/ajpcr/article/view/26707.
Section
Original Article(s)